| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | Complement inhibitor | JP2006508386 | 2004-06-02 | JP2007536894A | 2007-12-20 | ナン，マイルス，アンドリュー |
| The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases. | ||||||
| 2 | Compositions and methods related to argininosuccinate synthase | JP2013510085 | 2011-01-26 | JP2013527174A | 2013-06-27 | プリマ，ヴィクター; ワン，アルヴィン; モリナ，ガブリエル; ワン，ケヴィン，カ−ワン; スヴェトロフ，スタニスラフ，アイ． |
| アルギニノコハク酸合成酵素またはＰＥＧ化アルギニノコハク酸合成酵素を対象に投与し、内毒素を不活性化し、細菌性敗血症の可能性を低減し、患者の治療効果を向上する病原性グラム陰性細菌感染の治療的な処置のための工程および組成物を提供する。
|
||||||
| 3 | 生理活性脂質の使用 | JP2017530706 | 2015-12-01 | JP2017538704A | 2017-12-28 | モジュガン マソーディ，; エル ハディ ママドゥー ディオウム， |
| 本発明は、対象における炎症性疾患の治療及び/又は予防に使用するための酸素化脂肪酸アシルグリセロールを提供する。【選択図】なし | ||||||
| 4 | 自己免疫性１型糖尿病の免疫調節療法 | JP2016554671 | 2015-02-20 | JP2017520509A | 2017-07-27 | オーバン・ティハメル; ジャラヘジ・ヘヤム; ドーブニー・ナラ; ドーブニー・ピアーズ |
| 1型糖尿病の自己免疫を処置するための組成物は、治療的に有効な量のプレプロインスリンの2つ以上の重複フラグメントと、薬学的に許容可能なキャリアとを含むことができ、ポリペプチドフラグメントの少なくとも1つは抗原性である。 | ||||||
| 5 | アルギニノコハク酸合成酵素に関係する組成物および方法 | JP2013510085 | 2011-01-26 | JP6063378B2 | 2017-01-18 | プリマ,ヴィクター; ワン,アルヴィン; モリナ,ガブリエル; ワン,ケヴィン,カ−ワン; スヴェトロフ,スタニスラフ,アイ. |
| 6 | Complement inhibitor | JP2006508386 | 2004-06-02 | JP4772667B2 | 2011-09-14 | ナン，マイルス，アンドリュー |
| The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases. | ||||||
| 7 | OmpA and Asp14 in vaccine compositions and as diagnostic targets | US15477137 | 2017-04-03 | US10039815B2 | 2018-08-07 | Jason A. Carlyon |
| Anaplasma phagocytophilum surface proteins Asp14 and OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. Asp14 and/or OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to Asp14 and/or OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection. Because of the conserved invasin domains in the surface proteins, a wide range of Anaplasmatacaea infections may be diagnosed, treated or prevented using compositions of the invention. | ||||||
| 8 | Method and system for the treatment of medical conditions by intravenous therapy | US15150754 | 2016-05-10 | US09827264B1 | 2017-11-28 | Wyatt J. Palumbo |
| A method and system for identifying and treating various medical conditions caused by toxins, pathogens, hormonal imbalances and other factors involving intravenous therapy. | ||||||
| 9 | OMPA AND ASP14 IN VACCINE COMPOSITIONS AND AS DIAGNOSTIC TARGETS | US15477137 | 2017-04-03 | US20170202941A1 | 2017-07-20 | Jason A. Carlyon |
| Anaplasma phagocytophilum surface proteins Asp14 and OmpA and homologous genes from Anaplasmatacaea family members are used in compositions suitable for vaccines to treat or prevent infections caused by tick-born bacteria of the Anaplasmatacaea family. Asp14 and/or OmpA proteins or peptide fragments may be used in combination with other Anaplasmatacaea surface proteins to elicit an immune response. Furthermore, antibodies to Asp14 and/or OmpA proteins can be used in diagnostic methods to determine whether an individual has contracted an Anaplasmatacaea infection. Because of the conserved invasin domains in the surface proteins, a wide range of Anaplasmatacaea infections may be diagnosed, treated or prevented using compositions of the invention. | ||||||
| 10 | CHEMICAL AND BIOCHEMICAL ADDUCTS AS BIOMARKERS FOR ORGANOPHOSPHATE EXPOSURE | US15391614 | 2016-12-27 | US20170101441A1 | 2017-04-13 | John R. Cashman; Mary T. MacDonald |
| Provided are methods for identifying OP-adducted biomarkers of OP exposure as well as compounds containing OPs that can provide OP adducts and compounds of Formula 1 for eliciting antibodies that specifically and selectively bind to the OP adducts, wherein the Formula 1 compounds have the structure of OP-Peptide-Linker-CP, wherein CP is a carrier protein, OP represents a structure corresponding to that of a reactive organic phosphorous compound covalently modifying a tyrosine residue hydroxyl group of the peptide of Formula I and the other variable groups are as described herein. | ||||||
| 11 | Chemical and biochemical adducts as biomarkers for organophosphate exposure | US12937957 | 2009-04-14 | US09549991B2 | 2017-01-24 | John R. Cashman; Mary T. MacDonald |
| The present disclosure provides organophosphorous (OP) compounds of Formula (I), Formula (II) and Formula (III): OP-Peptide-Linker-CP (I), OP-Peptide-Linker (II); and wherein OP is including that structure corresponding to a reactive organophosphorous reagent, nerve agent or pesticide, or a pesticide P═S to P═O metabolite; P is the Sp or Rp stereoisomer; X is oxygen, sulfur, selenium or imino; R and R′ are as described; Peptide is a sequence of amino acids containing a serine, threonine or tyrosine to which the OP is attached, wherein the total number of amino acids is between 7 and 41; Linker is an amino acid or is derived from another bifunctional reagent capable of covalently attaching an OP-peptide to a CP; and CP is a carrier protein used to display haptens for antibody generation. The disclosure also provides methods for generating monoclonal or polyclonal antibodies specific for an OP-Peptide of a compound of Formula (I) or Formula (II) that can be used to diagnose the presence, identity, and quantity of OP adducts. | ||||||
| 12 | Methods and Devices for Rapid Assessment of Severity of Injury | US14536796 | 2014-11-10 | US20150064730A1 | 2015-03-05 | Kristian Bangert; Lars Otto Uttenthal |
| Methods and devices for rapid assessment of the severity of injury not due to a natural disease based upon measurement of neutrophil gelatinase-associated lipocalin (NGAL) are provided. | ||||||
| 13 | ANTI-TOXIN VACCINE COMPOSITIONS AND METHODS OF USE THEREOF | US13412601 | 2012-03-05 | US20120251542A1 | 2012-10-04 | Nilgun Tumer; Xiao-Ping Li |
| Compositions and methods for treatment of toxin poisoning are disclosed. | ||||||
| 14 | Methods and Devices for Rapid Assessment of Severity of Injury | US12302931 | 2007-05-30 | US20090197280A1 | 2009-08-06 | Kristian Bangert; Lars Otto Uttenthal |
| Methods and devices for rapid assessment of the severity of injury not due to a natural disease based upon measurement of neutrophil gelatinase-associated lipocalin (NGAL) are provided. | ||||||
| 15 | IMMUNOASSAY FOR VENOM DETECTION INCLUDING NONINVASIVE SAMPLE COLLECTION | US11550130 | 2006-10-17 | US20070141626A1 | 2007-06-21 | William Stoecker; Hernan Gomez; Jonathan Green; David McGlasson |
| Methods and immunoassays for diagnosing a bite or sting of a venomous organism in a patient having symptoms consistent with such a bite or sting are provided. A sample of venom is collected from the area of the suspected bite or sting using a swab and then contacted with an antibody that specifically binds to an antigenic site on venom present in the sample. Binding is then detected. The invention is illustrated by examples showing diagnosis of brown recluse spider bite, distinguishing it from other diagnoses with which it is often confused. This extremely sensitive test can detect venom antigens down to about 20 picograms even after the sample has been shipped and stored for periods of up to three weeks during the summer. | ||||||
| 16 | Methods and kit for diagnosing tick borne illnesses | US11066399 | 2005-02-25 | US20060194267A1 | 2006-08-31 | Aristo Vojdani |
| ELISA, Western Blot, and a peptide-based ELISA were applied to clinical specimens from patients with clinical symptoms of tick borne diseases, including Lyme disease. Peptides from different components of Borrelia during different cycles, including peptides from outer surface protein, leukocyte function associated antigens, immunodominant antigens, variable major proteins, and peptides from decorin-binding proteins of Borrelial subspecies (B. sensu stricto. B. afzelii, B. garinii) were used. Antibodies against specific peptides from Babesia and Ehrlichia were also measured. | ||||||
| 17 | IMMUNOMODULATORY THERAPY FOR TYPE 1 DIABETES MELLITUS AUTOIMMUNITY | EP15708257.9 | 2015-02-20 | EP3110436A1 | 2017-01-04 | Tihamer, Orban; Heyam, Jalahej; Daubeney, Nara; Daubeney, Piers |
| A composition for treating type 1 diabetes mellitus autoimmunity can include a therapeutically effective amount of two or more overlapping fragments of preproinsulin and a pharmaceutically acceptable carrier, wherein at least one of the polypeptide fragments is antigenic. | ||||||
| 18 | METHODS FOR RAPID ASSESSMENT OF SEVERITY OF A TRAUMA | EP07722631.4 | 2007-05-30 | EP2035835B1 | 2011-12-28 | BANGERT, Kristian; UTTENTHAL, Lars, Otto |
| Methods and devices for rapid assessment of the severity of injury not due to a natural disease based upon measurement of neutrophil gelatinase-associated lipocalin (NGAL) are provided. | ||||||
| 19 | CHEMICAL AND BIOCHEMICAL ADDUCTS AS BIOMARKERS FOR ORGANOPHOSPHATE EXPOSURE | EP09801832.8 | 2009-04-14 | EP2276510A2 | 2011-01-26 | CASHMAN, John, R.; MACDONALD, Mary, T. |
| Provided is a method to identify OP-adducted biomarkers of OP exposure as well as compounds containing OPs that can provide OP adducts. | ||||||
| 20 | COMPLEMENT INHIBITORS FROM TICKS | EP04735758.7 | 2004-06-02 | EP1629098A2 | 2006-03-01 | Nunn, Miles Andrew |
| The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases. | ||||||
QQ群二维码
意见反馈
意见反馈